China National Chemical said it filed for US antitrust approval with the Federal Trade Commission for its proposed $43 billion takeover of Swiss agrochemical company Syngenta.
ChemChina has submitted documentation required by the Hart-Scott-Rodino Act and expects the US antitrust process to be “on track,” the company said in an e-mail. The FTC, which oversees merger reviews along with the Justice Department, generally has 30 days to clear the proposed tie-up or issue a second request, seeking more information and a longer review period. When it’s a cash tender offer, the FTC has 15 days to review.
The proposed transaction already has been cleared by a US national security panel and won antitrust approval in Australia, where there are overlapping products between Syngenta and ChemChina’s Israeli-based generic agrochemical maker Adama.
Syngenta Chairman Michel Demare said this week he expects only a “few” concessions will be needed to get regulatory approval for ChemChina’s acquisition.
“The overlap is extremely small,” Demare said in a Bloomberg interview at the World Economic Forum in Davos. “There’s a few market concessions that will have to be made but nothing that will fundamentally change the business model of Syngenta.”
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI